Publications by authors named "A R Scortechini"
Article Synopsis
- The study evaluated the use of frontline TKI therapy in elderly patients (75 years or older) with chronic phase chronic myeloid leukemia (CP-CML) among a large cohort of 332 patients.
- Results showed that 85.8% of patients received imatinib (IM), while 14.2% were treated with second-generation TKIs (2G-TKI) like dasatinib and nilotinib, with a notable percentage starting on reduced doses.
- The findings indicated increased usage of IM after generic versions became available in Italy, but significant discontinuation rates due to resistance and toxicities were observed, highlighting the need for personalized treatment assessments and further studies on lower TKI doses.
Gaucher disease is a lysosomal storage disorder caused by functional glucocerebrosidase enzyme deficiency. Hepatosplenomegaly and hematological complications are found in both Gaucher disease and Acid Sphingomyelinase Deficiency, which is caused by acid sphingomyelinase dysfunction. The possible overlap in clinical presentation can cause diagnostic errors in differential diagnosis.
View Article and Find Full Text PDFDeterminants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
Cancer
September 2023
Background: Imatinib, dasatinib, and nilotinib are tyrosine kinase inhibitors (TKIs) approved in Italy for frontline treatment of chronic-phase chronic myeloid leukemia (CP-CML). The choice of TKI is based on a combined evaluation of the patient's and the disease characteristics. The aim of this study was to analyze the use of frontline TKI therapy in an unselected cohort of Italian patients with CP-CML to correlate the choice with the patient's features.
View Article and Find Full Text PDFTKIs long-term treatment in CML may lead to persistent adverse events (AEs) that can promote relevant morbidity and mortality. Consequently, TKIs dose reduction is often used to prevent AEs. However, data on its impact on successful treatment-free remission (TFR) are quite scarce.
View Article and Find Full Text PDFTreatment-free remission (TFR) has become a primary therapeutic goal in CML and is also considered feasible by international guidelines. TKIs dose reduction is often used in real-life practice to reduce adverse events, although its impact on TFR is still a matter of debate. This study aimed to explore the attitude of Italian hematologists towards prescribing TKIs at reduced doses and its impact on TFR.
View Article and Find Full Text PDF